PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3264604-7 1988 Our results suggest that MPTP can be toxic not only via MAO-B, but also via MAO-A activity and we propose PC12 as a model to study the intracellular mechanisms of MPTP and MPP+ toxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 25-29 monoamine oxidase B Rattus norvegicus 56-61 3101671-0 1986 Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 91-135 monoamine oxidase B Rattus norvegicus 68-87 3143167-3 1988 Deprenyl, a specific inhibitor of monoamine oxidase-B, the enzyme catalyzing the oxidation of MPTP into MPP+, blocked the lethal effect of MPTP, but gave no protection from MPP+-induced cell death. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 94-98 monoamine oxidase B Rattus norvegicus 34-53 3143167-3 1988 Deprenyl, a specific inhibitor of monoamine oxidase-B, the enzyme catalyzing the oxidation of MPTP into MPP+, blocked the lethal effect of MPTP, but gave no protection from MPP+-induced cell death. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 139-143 monoamine oxidase B Rattus norvegicus 34-53 2898342-6 1988 After pretreatment with the specific MAO B inhibitor, deprenyl, the rates of production of the two microsomal metabolites were enhanced, but the overall rate of MPTP conversion decreased by more than 60%. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 161-165 monoamine oxidase B Rattus norvegicus 37-42 3319563-4 1987 In rats, type B monoamine oxidase (MAO-B), which mediates the conversion of MPTP to MPP+, may act as an enzymatic barrier at brain microvessels, whereas in primates the enzyme, present mainly in astrocytes, appears important for bioactivation of MPTP into the toxic metabolite. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 76-80 monoamine oxidase B Rattus norvegicus 35-40 3319563-4 1987 In rats, type B monoamine oxidase (MAO-B), which mediates the conversion of MPTP to MPP+, may act as an enzymatic barrier at brain microvessels, whereas in primates the enzyme, present mainly in astrocytes, appears important for bioactivation of MPTP into the toxic metabolite. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 246-250 monoamine oxidase B Rattus norvegicus 35-40 3123604-3 1987 MPTP is oxidised to its neurotoxic metabolite, 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B (MAO B). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 85-104 3123604-3 1987 MPTP is oxidised to its neurotoxic metabolite, 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B (MAO B). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 106-111 2970526-3 1988 Our results demonstrate that, in cultures, MPTP is oxidized predominantly by monoamine oxidase B, since deprenyl but not clorgyline had an inhibitory effect on its metabolism. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 43-47 monoamine oxidase B Rattus norvegicus 77-96 3171572-10 1988 The low level of monoamine oxidase B in the nigrostriatal tract may help to explain the resistance of the rat to MPTP toxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 113-117 monoamine oxidase B Rattus norvegicus 17-36 3496045-1 1987 MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by monoamine oxidase B to its putative toxic metabolite MPP+ (1-methyl-4-phenylpyridinium ion) via MPDP+ (1-methyl-4-phenyl-2,3-dihydropyridinium ion). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 68-87 3496045-1 1987 MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by monoamine oxidase B to its putative toxic metabolite MPP+ (1-methyl-4-phenylpyridinium ion) via MPDP+ (1-methyl-4-phenyl-2,3-dihydropyridinium ion). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 6-50 monoamine oxidase B Rattus norvegicus 68-87 3102694-4 1987 Monoamine oxidase B inhibitors (e.g., pargyline, MDL 72145) relieve the inhibition caused by MPTP but not MPP+. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 93-97 monoamine oxidase B Rattus norvegicus 0-19 3123604-4 1987 MPTP toxicity is prevented by pretreatment with the MAO B inhibitor selegiline ((-)-deprenyl). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 52-57 3101671-0 1986 Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 137-141 monoamine oxidase B Rattus norvegicus 68-87 3097260-2 1986 A covalently bound metabolite is formed by MAO-B in vitro from MPTP, through a reaction almost completely inhibited by physiological concentrations of glutathione and significantly reduced by other sulfhydryl containing compounds. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 63-67 monoamine oxidase B Rattus norvegicus 43-48 3487052-2 1986 Conversion of MPTP to 1-methyl-4-phenylpyridine (MPP+) by monoamine oxidase-B (MAO-B) appears necessary for this neurotoxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 14-18 monoamine oxidase B Rattus norvegicus 58-77 3487052-2 1986 Conversion of MPTP to 1-methyl-4-phenylpyridine (MPP+) by monoamine oxidase-B (MAO-B) appears necessary for this neurotoxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 14-18 monoamine oxidase B Rattus norvegicus 79-84 3487052-6 1986 It is proposed that the conversion of MPTP to MPP+ occurs via MAO-B within serotonin and histamine neurons which may innervate the substantia nigra where the toxin MPP+ could be released and then taken up into the dopamine neurons. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 38-42 monoamine oxidase B Rattus norvegicus 62-67 3876524-0 1985 Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 72-116 monoamine oxidase B Rattus norvegicus 23-42 3878183-4 1985 Findings support the importance of MAO-B in the toxicity of MPTP and suggest that resistance of rat DA neurons to the neurotoxin is probably not due to species differences in MAO-B activity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 60-64 monoamine oxidase B Rattus norvegicus 35-40 3912685-2 1985 MPP+ can be formed by the oxidation of MPTP by monoamine oxidase B to the intermediate dihydropyridinium species, MPDP+, which is spontaneously transformed to MPP+. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 39-43 monoamine oxidase B Rattus norvegicus 47-66 2413402-3 1985 These results are consistent with the premise that MPP+, formed from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by the enzyme monoamine oxidase B, may be responsible for the toxicity observed after MPTP administration. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 69-113 monoamine oxidase B Rattus norvegicus 135-154 2413402-3 1985 These results are consistent with the premise that MPP+, formed from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by the enzyme monoamine oxidase B, may be responsible for the toxicity observed after MPTP administration. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 115-119 monoamine oxidase B Rattus norvegicus 135-154 2413402-3 1985 These results are consistent with the premise that MPP+, formed from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by the enzyme monoamine oxidase B, may be responsible for the toxicity observed after MPTP administration. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 207-211 monoamine oxidase B Rattus norvegicus 135-154 3876227-3 1985 MPTP oxidation in the brain may very well be mediated by MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 57-62 3876242-5 1985 These results support the concept that MPTP accumulates in serotonergic neurons where it is oxidized by monoamine oxidase B to MPP+, which is released and then is selectively accumulated in dopaminergic neurons via the dopamine uptake system. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 39-43 monoamine oxidase B Rattus norvegicus 104-123 3876524-3 1985 MPTP inhibited monoamine oxidase B (MAO-B) with both a reversible (competitive, Ki = 116 microM) and an irreversible time-dependent component, but inhibition by MPP+ was reversible and competitive (Ki = 180 microM). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 15-34 3876524-3 1985 MPTP inhibited monoamine oxidase B (MAO-B) with both a reversible (competitive, Ki = 116 microM) and an irreversible time-dependent component, but inhibition by MPP+ was reversible and competitive (Ki = 180 microM). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 36-41 3876524-4 1985 These results, together with previous findings on metabolism of MPTP to MPP+ by brain MAO-B, suggest that MPP+ is a simple inhibitor of MAO-A and MAO-B, but MPTP might be a "suicide substrate" inhibitor for MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 64-68 monoamine oxidase B Rattus norvegicus 86-91 3876524-4 1985 These results, together with previous findings on metabolism of MPTP to MPP+ by brain MAO-B, suggest that MPP+ is a simple inhibitor of MAO-A and MAO-B, but MPTP might be a "suicide substrate" inhibitor for MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 64-68 monoamine oxidase B Rattus norvegicus 146-151 3876524-4 1985 These results, together with previous findings on metabolism of MPTP to MPP+ by brain MAO-B, suggest that MPP+ is a simple inhibitor of MAO-A and MAO-B, but MPTP might be a "suicide substrate" inhibitor for MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 64-68 monoamine oxidase B Rattus norvegicus 146-151 3876524-4 1985 These results, together with previous findings on metabolism of MPTP to MPP+ by brain MAO-B, suggest that MPP+ is a simple inhibitor of MAO-A and MAO-B, but MPTP might be a "suicide substrate" inhibitor for MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 157-161 monoamine oxidase B Rattus norvegicus 86-91 3872811-1 1985 Chemical reactions of MPDP+, a recognized intermediate in the metabolic conversion of the neurotoxin MPTP by monoamine oxidase B into its major metabolite MPP+, were studied. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 101-105 monoamine oxidase B Rattus norvegicus 109-128 2861994-1 1985 Detailed studies have been carried out on the monoamine oxidase B-catalyzed bioactivation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by rat brain mitochondrial preparations. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 117-161 monoamine oxidase B Rattus norvegicus 46-65 2861994-1 1985 Detailed studies have been carried out on the monoamine oxidase B-catalyzed bioactivation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by rat brain mitochondrial preparations. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 163-167 monoamine oxidase B Rattus norvegicus 46-65 3871853-7 1985 MPTP was less potent as an inhibitor of MAO-B from rat brain in vitro (Ki = 106 microM). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 40-45 3872460-2 1985 N-Methyl-4-phenylpyridine (MPP+), a metabolite of MPTP formed by monoamine oxidase B, is accumulated into striatal and cerebral cortical synaptosomes by the dopamine and norepinephrine uptake systems, respectively, whereas MPTP itself is not accumulated. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 50-54 monoamine oxidase B Rattus norvegicus 65-84 3872460-2 1985 N-Methyl-4-phenylpyridine (MPP+), a metabolite of MPTP formed by monoamine oxidase B, is accumulated into striatal and cerebral cortical synaptosomes by the dopamine and norepinephrine uptake systems, respectively, whereas MPTP itself is not accumulated. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 223-227 monoamine oxidase B Rattus norvegicus 65-84 3871853-8 1985 In contrast to the inhibition of MAO-A, the inhibition of MAO-B by MPTP showed noncompetitive kinetics, was not fully reversible by dialysis and was time dependent. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 67-71 monoamine oxidase B Rattus norvegicus 58-63 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 352-356 monoamine oxidase B Rattus norvegicus 102-107 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 188-192 monoamine oxidase B Rattus norvegicus 102-107 26876935-7 2016 Selegiline, a monoamine oxidase type B inhibitor that is used as a therapeutic drug for Parkinson"s disease, also significantly inhibited the decrease in dopaminergic spontaneous firing induced by MPTP, but the effect was transient. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 197-201 monoamine oxidase B Rattus norvegicus 14-38 28807675-0 2017 Substantial protection against MPTP-associated Parkinson"s neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 31-35 monoamine oxidase B Rattus norvegicus 164-169 20045397-2 2010 L-deprenyl, an irreversible inhibitor of monoamine oxidase B, appears to protect or rescue dopaminergic nigral neurons from the toxic effects of 6-hydroxydopamine (6-OHDA) and 1-methyl-4 phenyl-1, 2, 3, 6-tetrahydropiridine (MPTP). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 225-229 monoamine oxidase B Rattus norvegicus 41-60 11566147-9 2001 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) effect was lesser and inhibited by deprenyl (MAO-B inhibitor). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-44 monoamine oxidase B Rattus norvegicus 97-102 12871570-4 2003 TV3326 preferentially inhibits MAO-B in the striatum and hippocampus, and the degree of MAO-B inhibition correlates with the prevention of MPTP-induced dopamine depletion. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 139-143 monoamine oxidase B Rattus norvegicus 88-93 11566147-9 2001 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) effect was lesser and inhibited by deprenyl (MAO-B inhibitor). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 46-50 monoamine oxidase B Rattus norvegicus 97-102 7849570-1 1994 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an inducer of parkinsonism, causes degeneration of nigro-striatal dopaminergic neurons by producing its neurotoxic metabolite, 1-methyl-4-phenylpiridium ion (MPP+), by monoamine oxidase B in glial cells. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-44 monoamine oxidase B Rattus norvegicus 221-240 9191089-4 1997 Hydrogen peroxide has also been reported to be produced via inhibition of NADH dehydrogenase by MPP + formed during oxidation of MPTP by MAO-B and by dopamine auto-oxidation following MA-induced dopamine release from synaptic vesicles within nerve terminals. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 129-133 monoamine oxidase B Rattus norvegicus 137-142 10567696-7 1999 The reduction by MPTP but not MPDP(+) was completely prevented by pargyline, a type B monoamine oxidase (MAO-B) inhibitor, in the synaptosomes. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 17-21 monoamine oxidase B Rattus norvegicus 105-110 10567696-8 1999 The results indicate that involvement of MAO-B is critical for the reduction of ubiquinone by MPTP but that MPDP(+) is a reductant of ubiquinone per se. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 94-98 monoamine oxidase B Rattus norvegicus 41-46 9813295-9 1998 These results indicate that the difference in the pharmacokinetics of exogenously applied MPTP in the striatum and nucleus accumbens may be due to a difference in uptake in these regions, and that the difference in pharmacokinetics of endogenously produced MPP+ may be due to differences in both uptake and monoamine oxidase-B activity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 90-94 monoamine oxidase B Rattus norvegicus 307-326 9396088-2 1997 Firstly, we compared the neurotoxicity of MPTP, mediated by monoamine oxidase (MAO)-B, to that of 1-methyl-4-(2"-methylphenyl)-1,2,3,6-tetrahydropyridine (2"-CH3-MPTP), an analogue oxidized by MAO-A and MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 42-46 monoamine oxidase B Rattus norvegicus 60-85 9396088-2 1997 Firstly, we compared the neurotoxicity of MPTP, mediated by monoamine oxidase (MAO)-B, to that of 1-methyl-4-(2"-methylphenyl)-1,2,3,6-tetrahydropyridine (2"-CH3-MPTP), an analogue oxidized by MAO-A and MAO-B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 42-46 monoamine oxidase B Rattus norvegicus 203-208 9274805-6 1997 MPTP effects were inhibited by L-deprenyl, a MAO-B inhibitor. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 0-4 monoamine oxidase B Rattus norvegicus 45-50 7849570-1 1994 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an inducer of parkinsonism, causes degeneration of nigro-striatal dopaminergic neurons by producing its neurotoxic metabolite, 1-methyl-4-phenylpiridium ion (MPP+), by monoamine oxidase B in glial cells. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 46-50 monoamine oxidase B Rattus norvegicus 221-240 2122806-3 1990 The effect of MPTP, but not that of MPP+, was prevented by deprenyl, an inhibitor of MPTP conversion to MPP+ via monoamine oxidase type B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 14-18 monoamine oxidase B Rattus norvegicus 113-137 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 145-190 monoamine oxidase B Rattus norvegicus 88-93 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 192-196 monoamine oxidase B Rattus norvegicus 88-93 8302304-9 1993 Selegiline doses that were too small to cause inhibition of MAO-B substrate oxidation rescued the MPTP-damaged dSNns. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 98-102 monoamine oxidase B Rattus norvegicus 60-65 1912294-1 1991 Evidence that partially oxidized piperidine derivatives such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 96-140 monoamine oxidase B Rattus norvegicus 194-213 1912294-1 1991 Evidence that partially oxidized piperidine derivatives such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 96-140 monoamine oxidase B Rattus norvegicus 215-220 1912294-1 1991 Evidence that partially oxidized piperidine derivatives such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 142-146 monoamine oxidase B Rattus norvegicus 194-213 1912294-1 1991 Evidence that partially oxidized piperidine derivatives such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 142-146 monoamine oxidase B Rattus norvegicus 215-220 8200437-2 1994 The current explanation for the rat resistance is that most of the MPTP is converted into the toxic metabolite 1-methyl-4-phenylpyridium (MPP+) by the MAO-B present in the brain vessel endothelium. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 67-71 monoamine oxidase B Rattus norvegicus 151-156 1488908-8 1992 The neuroprotective effect of selegiline is multiple, with the inhibition of MAO-B it can stop the production of neurotoxin MPP+ (arising from MPTP) and its uptake into the nerve endings respectively. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 143-147 monoamine oxidase B Rattus norvegicus 77-82 2122806-3 1990 The effect of MPTP, but not that of MPP+, was prevented by deprenyl, an inhibitor of MPTP conversion to MPP+ via monoamine oxidase type B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 85-89 monoamine oxidase B Rattus norvegicus 113-137 2133093-4 1990 A comparison with the corresponding values for the monoamine oxidase B (MAO-B) catalyzed reaction (4.37 and 9.35, respectively) suggests that either these enzymes catalyze the ring alpha-carbon oxidation of MPTP by different pathways or that the initial one-electron transfer to generate an aminium radical intermediate previously proposed for both enzyme systems is reversible in the case of MAO-B and irreversible in the case of cytochrome P-450IA1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 207-211 monoamine oxidase B Rattus norvegicus 51-70 2133093-4 1990 A comparison with the corresponding values for the monoamine oxidase B (MAO-B) catalyzed reaction (4.37 and 9.35, respectively) suggests that either these enzymes catalyze the ring alpha-carbon oxidation of MPTP by different pathways or that the initial one-electron transfer to generate an aminium radical intermediate previously proposed for both enzyme systems is reversible in the case of MAO-B and irreversible in the case of cytochrome P-450IA1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 207-211 monoamine oxidase B Rattus norvegicus 72-77 2133093-4 1990 A comparison with the corresponding values for the monoamine oxidase B (MAO-B) catalyzed reaction (4.37 and 9.35, respectively) suggests that either these enzymes catalyze the ring alpha-carbon oxidation of MPTP by different pathways or that the initial one-electron transfer to generate an aminium radical intermediate previously proposed for both enzyme systems is reversible in the case of MAO-B and irreversible in the case of cytochrome P-450IA1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 207-211 monoamine oxidase B Rattus norvegicus 393-398 2126479-4 1990 Both 3-AP and another pyridine neurotoxin, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP), potently inhibited in vitro MAOB activity and in contrast weakly inhibited MAOA activity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 43-88 monoamine oxidase B Rattus norvegicus 125-129 2126479-4 1990 Both 3-AP and another pyridine neurotoxin, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP), potently inhibited in vitro MAOB activity and in contrast weakly inhibited MAOA activity. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 90-94 monoamine oxidase B Rattus norvegicus 125-129 2298362-8 1990 MAO-B inhibitors (pargyline [55%], deprenyl [43%]) but not MAO-A inhibitors (clorgyline [91%]) significantly decreased the frequency of duodenal ulcers suggesting that, like MPTP-induced parkinsonism, formation of a toxic metabolite, probably 1-methyl-4-phenyl-pyridinium is involved. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 174-178 monoamine oxidase B Rattus norvegicus 0-5